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Chronic urticaria may be characterized by condi-
tional autoantibodies against the a-chain of the high-
af®nity receptor for IgE (FceRI). These autoanti-
bodies are termed conditional as they only recognize
unoccupied FceRI. The same conditional reactivity
pattern has also been found in sera of atopic and
normal healthy donors. Any condition resulting in
accessibility of FceRI will render these autoanti-
bodies anaphylactogenic. This ®nding offers a unify-
ing hypothesis for the manifestation of different
forms of urticaria. Non-immunologic triggers may
thereby in¯uence directly or indirectly the number
of accessible FceRI allowing the conditional auto-
antibodies to induce urticaria symptoms. Key words:
allergy/high af®nity IgE receptor (FceRI)/histamine
release/IgE/phage display/recombinant antibodies. Journal
of Investigative Dermatology Symposium Proceedings
6:150±152, 2001
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llergic urticaria as the least common form of this
disease is assumed to be IgE mediated; however,
nonallergic urticaria may also be indirectly IgE
mediated, if we assume that autoantibodies against
the a-chain of the high-af®nity IgE receptor (FceRI
a-chain) play the pathophysiologic role (Fiebiger et al, 1996;
Greaves, 2000).
The presence of such autoantibodies has been shown by
immunologic means, but their physical demonstration has been
complicated by the presence of anti-IgE antibodies that would
interfere in diagnostic and cellular immuno assays (Horn et al, 1999;
Marone et al, 1999; Sabroe et al, 1999; Zuberbier et al, 2000).
In order to understand the pathophysiologic mechanisms and to aid
in the future therapy of urticaria, it would therefore be very
important to document the molecular existence of anti-FceRI
antibodies.
In the past the same situation prevailed with anti-IgE antibodies
that were believed to be an in vitro artifact. After we had cloned
anti-IgE antibodies from the human rearranged immunoglobulin
repertoire, it became obvious that such antibodies may even play a
pathophysiologic role (Vogel et al, 1993; StaÈmp¯i et al, 1994;
Rudolf et al, 1996). We used the technique of phage display to
perform an immunoglobulin variable chain repertoire cloning in
order to ®nd human anti-IgE antibodies. The present utilization of
humanized anti-IgE antibodies for the therapy of allergies has also
elucidated the potential role of natural anti-IgE antibodies (Barnes,
2000; Fahy, 2000; Fick et al, 2000).
ANTI- FCeRI AUTOANTIBODIES IN NORMALS
As we had previously described anti-FceRI autoantibodies in
normals (Horn et al, 1999), our ®rst interest was to clone such
autoantibodies and to compare these with antibodies occuring in
urticaria patients. The interest in these natural autoantibodies also
lies in the fact that one would have to assume that such
autoantibodies would not have a pathophysiologic role and
would clearly be different from autoantibodies that may occur in
urticaria patients.
The anti-FceRI antibodies we cloned from normal blood donors
had extremely interesting properties. First, their heavy chains were
in germline con®guration, but were still of high af®nity for the a-
chain of FceRI. When tested on normal basophils, these antibodies
expressed in an eucaryotic cell line as full-length antibodies, were
not anaphylactogenic; however, if normal basophils were stripped
of their surface IgE by a lactic acid treatment, the anti-FceRI
autoantibodies became anaphylactogenic. As we found that the
antibodies perfectly stained a transfectoma cell line expressing the
a-chain of the IgE receptor, we had to conclude that these
autoantibodies only recognized IgE receptor expressing cells if the
IgE receptor was not occupied. We could con®rm this ®nding by
re-sensitizing normal basophils with IgE and thereby preventing the
anaphylactogenic activity of the autoantibodies.
Based on these data we termed the autoantibodies conditional
autoantibodies. They partly ful®lled the principle of recognizing a
hidden antigen, but the antigen was not hidden by compartmental-
ization or through its location within the cell, but only by the
condition that the receptor had to be occupied or not.
CHARACTERIZATION OF AUTOANTIBODIES FROM
URTICARIA PATIENTS
Using the same technique of antibody phage display, we cloned
autoantibodies from a pool of B cells from four urticaria
patients. The unexpected ®nding was that from 12 randomly
selected antibodies we found only one identical immunoglobu-
lin heavy chain. Most surprisingly this heavy chain was identical
to the heavy chain previously found in the most frequently
isolated antibody from a normal blood donor. At present it is
not known whether antibodies of other speci®cities do exist in
urticaria patients, but taking into account our isolation and
selection principles it was most likely no coincidence that we
ended up with the same heavy chain antibodies as the ones
found in normal donors.
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CONDITIONAL AUTOANTIBODIES AS A UNIFYING
HYPOTHESIS IN URTICARIA
Figure 1 depicts a hypothesis that we propose for the role of anti-
FceRI antibodies in urticaria. The presence of autoantibodies
against the a-chain of the IgE receptor has been described by others
(Fiebiger et al, 1996; Greaves, 2000). In this hypothesis, we would
like to propose the model that any disturbance in a given
homeostasis or equilibrium between the number of IgE receptors,
the degree of occupancy of IgE receptors, the level of free versus
receptor bound IgE, and the level of conditional autoantibodies
may be responsible for the manifestation of urticaria.
Non-speci®c and non-IgE mediated mechanisms may lead to an
increased expression of IgE receptors on basophils and mast cells
(Stallman et al, 1977; Chen et al, 1999). If IgE levels are unaltered
during the same period, then a large number of surface receptors
may now become available for the conditional anti-FceRI
autoantibody and the induction of symptoms by these antibodies.
A similar phenomenon may be achieved if the number of cells
expressing IgE receptors is increased locally, either through local
proliferation or through an extravasation of chemotactically
attracted cells with free receptors.
As the conditional autoantibodies can also bind to the
recombinant a-chain of FceRI in in vitro assays (Pachlopnik et al,
1998), it may be assumed that the secreted form of the a-chain as it
occurs in serum (Saban et al, 1994) may actually become an agonist
or antagonist for the autoantibodies and interfere with the
postulated equilibrium of the involved reaction partners to induce
urticaria symptoms.
The IgE level by itself, of course, will determine the extent of
free IgE receptors. Recently, during clinical evaluation of thera-
peutic anti-IgE antibodies it has been shown that they down-
regulated the IgE receptor density on basophils and mast cells (Saini
et al, 1999). Thus, IgE alone may be responsible for the regulation
of the IgE receptor expression, which might link autoimmune
forms of urticaria to the IgE-mediated triggerings of allergic
urticaria.
The proposed hypothesis would also allow for triggering
mechanisms in urticaria that have so far not been associated with
immune mechanisms, e.g., cold, sun exposure, alcohol excess,
endocrine disorders, and emotional stress. All these triggers may
lead to an altered local blood supply or affect IgE receptor gene
expression. Our hypothesis would also offer an explanation why
many people suffer only occasionally from mild forms of urticaria,
as the antibodies in normals and urticaria patients are in germline
con®guration and would not need to be produced by an
autoimmune response. If the so-called conditional autoantibodies
belong to the pool of natural antibodies, then it can be envisaged
that many people may undergo a short period of acute urticaria
symptoms without recognizing the symptoms as a quasi normal
conditional autoimmune state.
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